SCHEMBL17290366

SCHEMBL17290366

COC(=O)c1ccc(-c2cc(O)n(C)n2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.49
HPGD P15428 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
CA1 P00915 4/20 0.47
CA2 P00918 4/20 0.47
CA12 O43570 3/20 0.47
CA9 Q16790 3/20 0.47
CA14 Q9ULX7 3/20 0.47
CA7 P43166 2/20 0.47
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
EGFR P00533 1/20 0.44
ERN1 O75460 1/20 0.44
POLB P06746 1/20 0.44
TLR8 Q9NR97 1/20 0.44
ALDH1A3 P47895 1/20 0.44
XDH P47989 1/20 0.44
KDM4E B2RXH2 2/20 0.43
LMNA P02545 1/20 0.43
GAA P10253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13975284 0.85 TLR8 (0.50) ALDH1A1HPGDSMN1; SMN2CA1CA2
SCHEMBL4028684 0.84 CA12 (0.51) ALDH1A1HPGDSMN1; SMN2CA1CA2
SCHEMBL31735384 0.82 MEN1 (0.57) ALDH1A1HPGDSMN1; SMN2MEN1KMT2A
SCHEMBL17290757 0.78 MEN1 (0.50) ALDH1A1HPGDSMN1; SMN2CA9MEN1
SCHEMBL17295319 0.78 MEN1 (0.50) ALDH1A1HPGDSMN1; SMN2CA9MEN1
SCHEMBL2629323 0.76 JMJD6 (0.60) ALDH1A1HPGDSMN1; SMN2CA1CA2
SCHEMBL7846262 0.76 CHRNB2 (0.47) LMNA
Tert-Butyl Formate SCHEMBL28024807 0.75 ALDH1A1 (0.41) ALDH1A1HPGDSMN1; SMN2MEN1KMT2A
SCHEMBL8892611 0.75 ESRRA (0.53) ALDH1A1HPGDSMN1; SMN2MEN1KMT2A
SCHEMBL13874244 0.75 JMJD6 (0.58) ALDH1A1HPGDSMN1; SMN2CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9682938-B2 Pyrazolone derivatives as nitroxyl donors CARDIOXYL PHARMACEUTICALS, INC. (US) 2017-06-20 US disclosed
EP-3148972-A1 PYRAZOLONE DERIVATIVES AS NITROXYL DONORS Cardioxyl Pharmaceuticals Inc. (US) 2017-04-05 EP disclosed
WO-2015183839-A1 PYRAZOLONE DERIVATIVES AS NITROXYL DONORS CARDIOXYL PHARMACEUTICALS, INC. (US) 2015-12-03 WO disclosed
US-20150344437-A1 PYRAZOLONE DERIVATIVES AS NITROXYL DONORS THE JOHNS HOPKINS UNIVERSITY 2015-12-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150344437-A1 PYRAZOLONE DERIVATIVES AS NITROXYL DONORS TNNI3, PFKP, NOX5 ALDH1A1 1883/4885HPGD 19/4885SMN1; SMN2 1078/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.